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ABSTRACT
Objectives: This study was undertaken to develop a new
questionnaire, the Cancer Therapy Satisfaction Question-
naire (CTSQ), to focus on the issues oncology patients
consider when evaluating chemotherapy in terms of
expectations and satisfaction.
Methods: Items of the CTSQ were generated through
the review of responses from interviews with oncology
patients, physicians, and nurses. Analysis of the data was
stratiﬁed by disease stage, disease type, and country to
explore potential differences between these groups. Two
rounds of face and content validity testing were then con-
ducted.
Results: Patients explained their hopes for efﬁcacy and
factors related to treatment satisfaction. Content validity
testing in 30 patients, followed by additional testing in 10
patients on oral therapy, suggested that patients felt the
questionnaire was clear, comprehensive, relevant, and
easy to complete. Minor revisions were implemented to
improve clarity, resulting in deletion of 12 items, modiﬁ-
cation of 17 items and the rewording of “chemotherapy”
to “cancer therapy” to ensure patients on oral therapy
were able to respond. The CTSQ contains 21 items and
assesses seven domains: Expectations of cancer therapy,
Feelings about side effects, Oral cancer therapy adher-
ence, Convenience, Satisfaction with cancer therapy,
Stopping cancer therapy, and Reasons for nonadherence.
Conclusions: The CTSQ was designed for adults with a
wide range of cancer types and stages, receiving a variety
of cancer treatment formulations. A validation study is
currently underway to examine the psychometric proper-
ties, further reﬁne the questionnaire and develop scoring
methods for the CTSQ.
Keywords: cancer, chemotherapy, patient outcome
assessment, questionnaire design, satisfaction.
Introduction
Patients receiving chemotherapy tend to work
closely with their physicians and are typically
involved in their treatment decisions. When making
decisions to start or continue treatment, patients
often consider numerous factors, including treat-
ment expectations of efﬁcacy and side effects, satis-
faction with medical care, satisfaction with the
management of side effects, satisfaction with treat-
ment modality or dosage form (intravenous [IV] or
oral) and, possibly, life satisfaction [1–3]. All of
these factors can directly inﬂuence patients’ satisfac-
tion with treatment overall. Moreover, patients’
preferences and their assessments of the risks/bene-
ﬁts associated with chemotherapy may inﬂuence
their decisions to continue treatment and ultimately
determine their satisfaction with the outcome of
therapy [1,3].
Because patient satisfaction might reveal addi-
tional factors relevant to the treatment process and
outcome of chemotherapy, a literature review [4]
was conducted to determine whether an instrument
that assesses oncology patients’ expectations, satis-
faction, and preferences related to chemotherapy
treatment has been developed. No instruments that
adequately assess patient expectations or satisfac-
tion with chemotherapy were identiﬁed. The satis-
faction measures identiﬁed in this review primarily
addressed patients’ satisfaction with care [1,2], sat-
isfaction with adjuvant therapy [3] or preferences
related to chemotherapy-induced emesis [5]. Few
articles offered descriptions about the outcome tool
used [6] and most asked the simple question:
“Which treatment do you prefer? [7–9]” Most arti-
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cles focused on decision tree analysis, time trade-off
and decision aids—that is, the ways in which
patients make decisions to take or refuse treatment
[10–13]. Patient preferences identiﬁed in this litera-
ture review included oral chemotherapy rather than
IV chemotherapy medication [14], home treatment
over outpatient clinic care [1] and follow-up care
with primary physicians rather than oncologists
[15]. Identiﬁed patient preferences for taking chem-
otherapy also indicated that survival and toxicity
trade-offs may differ among patients with different
tumor types. For example, breast cancer patients
have been found to accept aggressive treatment with
severe side effects while knowing that the chances of
increased survival time may be minimal [16]. How-
ever, another study indicated that nonsmall cell lung
cancer patients were not willing to undergo chem-
otherapy if minimal survival beneﬁts and severe side
effects were to be expected [17].
Measuring Satisfaction
The measurement of satisfaction is an emotive eval-
uation, which enables the assessment of the appro-
priateness of the perceived quality of treatment to
patient expectations. Satisfaction is deﬁned as a
pleasant feeling caused by the fulﬁllment of expec-
tations [18–20].
Satisfaction is the result of a psychological proc-
ess, which involves the comparison of the perceived
performance of a given treatment to the patient’s
initial expectations [18,21]. The positive or negative
opinion and the future use or discontinuation of the
treatment depends mainly on patient satisfaction or
dissatisfaction. The relationship between patient
satisfaction, intentions and adherence behavior has
been demonstrated in both commercial and health-
care ﬁelds [22–24]. Indeed, in the ﬁeld of health
care, adherence with treatment largely depends on
the patient’s satisfaction with the treatment or med-
ical service received.
The main objective of this study was to design a
questionnaire for use in the United States (American
English) to assess satisfaction with and preference
for chemotherapy treatment. The questionnaire
would be used across a range of cancer types/stages
and treatment formulations, suitable for cross-cul-
tural adaptation and in multinational clinical trials.
Methodology
Stage 1: Item Generation Interviews and Focus 
Group Discussions
Oncology patients in the United States (n = 60), UK
(n = 5) and France (n = 5) were interviewed prima-
rily during face-to-face interviews. Some interviews
were conducted over the telephone. In-depth inter-
views were conducted in the UK and France to con-
sider any cultural differences. Oncologists recruited
patients between 18 and 75 years of age, who were
diagnosed with breast, colorectal or lung cancer and
who were ﬂuent in the native tongue of the target
country. Patients were in either the early or
advanced stage of disease. For breast cancer only,
survivors were also included. Patients must have
completed at least one cycle of chemotherapy during
the past 12 months, except for breast cancer survi-
vors, who must have completed at least one cycle of
chemotherapy two to 10 years ago. These interviews
explored global assessments of the patient experi-
ence, including current health and health-related
quality of life (HRQoL), as well as more speciﬁc
issues related to expectations, perceptions, satisfac-
tion with treatment and associated factors.
In addition to patient interviews, nurse and phy-
sician interviews were conducted to identify key
issues relevant to the management and treatment of
cancer from the health professionals’ point of view.
Focus group discussions were conducted with 14
oncology nurses in the United States and telephone
interviews were conducted with nurses in the UK
(n = 2) and in France (n = 2), all specializing in
oncology. Nurses represented hospital, academic
and clinic settings and were currently treating can-
cer patients. During these discussion groups and
interviews, nurses’ perceptions of patients’ opinions
and expectations about chemotherapy treatment
and overall management and treatment of cancer
were collected. The objectives of the discussions and
interviews were to identify aspects of the manage-
ment and treatment of cancer that are important to
patients and to explore the nurses’ perceptions of
the patients’ preferences, expectations, and satisfac-
tion with treatment.
Additionally, seven physicians were interviewed
by telephone for approximately 1 h per interview.
Physicians represented hospital, academic, and
clinic settings and were currently treating oncology
patients. These interviews speciﬁcally enquired into
physicians’ opinions about actual disease manage-
ment, cancer treatments, perceptions of treatments,
improvements needed in the treatment and manage-
ment of symptoms and the physicians’ opinions
regarding patients’ most bothersome symptoms and
factors that inﬂuence patient adherence.
Stage 2: Qualitative Analysis and Item Generation
Data collected through structured interviews were
recorded and transcribed verbatim. Verbatim
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patient, nurse, and physician comments were com-
prehensively reviewed and analyzed, then organized
by domains and types of psychosocial correlates.
These domains, correlates and framework formed
the basis for the patients’ perceptions conceptual
model and hypotheses. Responses and concerns
were grouped together to elicit the domains impor-
tant to this patient population. Potential differences
in patient perspectives by cancer type, stage of dis-
ease, country, and treatment type were evaluated
by reviewing the similarities and differences in
patients’ responses.
Using the results of the qualitative analysis, items
were generated to use, as much as possible, patient
phraseaology. Items, response choices and recall
periods were developed for clarity, conciseness, and
with lack of jargon.
Stage 3: Content Validity Testing
The content validity of the newly developed ques-
tionnaire was tested in 10 patients with breast can-
cer, 10 patients with colorectal cancer and 10
patients with lung cancer in the United States with
early- and advanced-stage disease, using established
cognitive debrieﬁng techniques. These 1-h, in-
person interviews involved different participants
than those who participated in the item generation
phase. The interviews aimed to assess the clarity,
understandability, and appropriateness of all
instructions, questionnaire items, and response con-
tinuums. Furthermore, content validity testing was
performed to ensure ease of comprehension on ﬁrst
reading.
Each interview transcript was comprehensively
reviewed and analyzed qualitatively for content;
items which were not well-understood or problem-
atic were reworded. In addition, responses to each
item on the questionnaire were entered into an
Excel database to calculate means, standard devia-
tions and ﬂoor and ceiling effects for each item. If
more than 60% of the population reported the
highest level of satisfaction for a particular item,
the item was considered a candidate for deletion,
because the ceiling effect would be quite high Cor-
relations between item responses were examined for
particular items that respondents felt were redun-
dant with other items. If the correlation was greater
than 0.7, the item was ﬂagged as a candidate for
deletion. It is important to note that items were not
deleted using these statistical criteria if the item was
mentioned by several patients or nurses in the inter-
view stage, because these were then felt to be of
great importance to patients and therefore should
be tested further in psychometric validation.
Stage 4: Qualitative Retesting of 
Revised Questionnaire
To ensure the questionnaire was understood by
those taking oral therapy and to assess whether
changes to the questionnaire implemented pursuant
to the content validity testing (Stage 3) were still
understood by respondents, an additional content
validity test was conducted with 10 adults with
breast cancer who were taking oral therapy. Half of
the patients recruited were in stage I or II and the
other half were in stage III or IV. One-hour face-to-
face interviews were conducted with patients with
early-stage cancer and telephone interviews were
conducted with patients with advanced-stage can-
cer. After completion of the questionnaire, the par-
ticipants were asked speciﬁc questions about their
impressions of the questionnaire, their understand-
ing of each question and their opinion of using
the word “chemotherapy” throughout the question-
naire and if the questionnaire encompassed all ther-
apies and in particular their own therapy.
Using the same qualitative methodology as pre-
viously described, additional modiﬁcations to the
wording of the questionnaire were undertaken
based on the results of the interviews.
Results
Results of Item Generation
Patient  interviews. Seventy patients were inter-
viewed: 60 from the United States, ﬁve from the UK
and ﬁve from France. In general, differences in
responses from patients and clinicians between the
countries were minor and, because of the small sam-
ple size, they are not discussed in detail. Table 1
provides the clinical and sociodemographic charac-
teristics of the study sample. The majority of
patients were newly diagnosed with cancer, mean
time since diagnosis was 2.57 years (±2.9), and
most patients stated their health was good (34%,
n = 24), very good (24%, n = 17), or fair (20%,
n = 14). In accordance with the study design, the
population was well distributed by cancer type;
40% (n = 28) were diagnosed with breast cancer,
34% (n = 24) with colorectal cancer and 26%
(n = 18) with lung cancer. All survivors were breast
cancer survivors (11%, n = 8), and the remaining
population included early-stage (46%, n = 32) and
advanced-stage patients (43%, n = 30). Although
the majority of patients had received only IV ther-
apy (87%, n = 61), three patients (4%) had received
oral chemotherapy only and six patients (9%) had
received both oral chemotherapy and IV treatment.
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Table 2 details the sex of patients by cancer type
and stage.
Clinician interviews: oncology nurses and
oncologists. The nurse and oncologist characteris-
tics are provided in Table 2. Two focus groups
including seven nurses each were conducted in the
United States (one in Los Angeles and one in Phil-
adelphia) with nurses specializing in oncology.
Additionally, nurses were interviewed in the UK
(n = 2) and in France (n = 2). The majority of nurses
practiced in a private setting (67%, n = 12) versus a
hospital setting (33%, n = 6). Seven oncologists
were interviewed: ﬁve in the United States, one in
Table 1 Item generation—patients’ clinical and sociodemographic characteristics
Total patients USA = 60 UK = 5 France = 5 Total = 70
Sex
Male 13 (22%) 2 (40%) 2 (40%) 17 (24%)
Female 47 (78%) 3 (60%) 3 (60%) 53 (76%)
Age
Mean 59 ± 9.8 56.2 ± 15.5 69.8 ± 6.0 61.6 ± 10.5
Range 38–75 39–74 70–76 38–76
Education level
High school without graduation or less 11 (18%) 1 (20%) 2 (40%) 14 (20%)
High school diploma/GED 19 (32%) 0 2 (40%) 21 (30%)
Vocational school or some college 14 (23%) 1 (20%) 1 (20%) 16 (23%)
College degree; undergraduate 10 (17%) 0 0 10 (14%)
Graduate degree 5 (8%) 0 0 5 (7%)
Missing data 1 (2%) 3 (60%) — 4 (6%)
Patient-reported health status
Excellent 6 (10%) 0 1 (20%) 7 (10%)
Very good 17 (28%) 0 0 17 (24%)
Good 21 (35%) 2 (40%) 1 (20%) 24 (34%)
Fair 10 (17%) 2 (40%) 2 (40%) 14 (20%)
Poor 6 (10%) 1 (20%) 1 (20%) 8 (11%)
Cancer type and stage
Breast (100% female) 26 (43%) 1 (20%) 1 (20%) 28 (40%)
Early 12 1 0 13
Advanced 7 0 0 7
Survivor 7 0 1 8
Colorectal (71% female) 20 (33%) 2 (40%) 2 (40%) 24 (34%)
Early 10 1 1 12
Advanced 10 1 1 12
Lung (44% female) 14 (23%) 2 (40%) 2 (40%) 18 (26%)
Early 5 1 1 7
Advanced 9 1 1 11
Chemotherapy administration route
IV 53 (88%) 4 (80%) 4 (80%) 61 (87%)
Oral 3 (5%) 0 0 3 (4%)
Oral and IV 4 (7%) 1 (20%) 1 (20%) 6 (9%)
GED, General Educational Development.
Table 2 Nurse and oncologist characteristics
Total nurses and oncologists
characteristics
USA = 19 UK = 3 France = 3
Nurses
(n = 14)
Oncologists
(n = 5)
Nurses
(n = 2)
Oncologist
(n = 1)
Nurses
(n = 2)
Oncologists
(n = 1)
Sex
Male 0 4 0 1 0 0
Female 14 1 2 0 2 1
Type of practice
Hospital/academic 5 3 1 1 0 0
Private 9 2 1 0 2 1
Number of years in oncology: 10 21 12 8 20 6
Mean (years)
Tumor type treated (%) N/A N/A N/A
Lung cancer 23% 0% 10%
Colorectal cancer 17% 50% 40%
Breast cancer 33% 0% 40%
Other cancers 27% 50% 10%
N/A, not applicable; distribution of tumor types treated was not collected from oncology nurses.
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the UK and one in France. The majority of oncolo-
gists were men (71%, n = 5), and the majority prac-
ticed in either a hospital or academic setting (57%,
n = 4). Predominately, these physicians had experi-
ence using chemotherapy to treat breast cancer,
colorectal cancer and, to lesser degree, lung cancer
patients.
Expectations. Predominately, patients described
their rationale for deciding to undergo chemother-
apy treatment as a necessity rather than a choice.
They often described the decision as a choice
between life and death. Nonetheless, patients’ expec-
tations about the treatment experience and its out-
comes varied signiﬁcantly. Some patients stated they
did not have expectations, either because they felt
chemotherapy was their only option or because they
had no background knowledge about chemother-
apy. Others expressed generalized hopes that chem-
otherapy would “help” them or would “work,”
without expressing speciﬁc expectations.
Breast cancer patients were far more likely to
expect remission or eradication of their cancer due
to chemotherapy treatment. However, when asked
why they chose chemotherapy, colorectal and lung
cancer patients were less optimistic. They tended to
view chemotherapy as a means by which to prolong
life or decrease the severity of their cancer, rather
than actually offering a cure.
Although breast cancer patients’ expectations
were more optimistic than those of lung and color-
ectal cancer patients, these differences may be due
to the fact that the majority of advanced-stage
patients (77%) suffered from colorectal (n = 12) or
lung (n = 11) cancer. Both colorectal and lung can-
cers are typically diagnosed at a more advanced
stage than breast cancer and treatment is less likely
to result in remission. Indeed, when examining the
data by stage, it was observed that advanced-stage
patients were less optimistic or hopeful for a cure
and were more likely to hope for prolonged life or
decreased disease severity; this was even the case for
advanced breast cancer patients.
According to nurses and physicians, patients’
hopes for survival were very strong and expecta-
tions regarding the efﬁcacy of medications took the
form of hope mixed with denial. This situation
results in patients who are overly optimistic about
the effects of chemotherapy, and are therefore dis-
appointed when chemotherapy does not eliminate
their tumors. Nurses and physicians further
explained that expectations of side effects depend
on patients’ previous experiences with other family
or friends with cancer, what they have heard about
chemotherapy from others and/or the portrayal of
the chemotherapy experience in the media. Results
from the patient interviews suggest that patients
with early stage or breast cancer had high expecta-
tions for a cure, whereas patients with advanced-
stage cancer did not. This indicates a slight depar-
ture from the nurse and oncologist perspective,
although it is certainly possible that the early-stage
patients were overly optimistic. However, this con-
clusion is not conﬁrmed, as nurses and physicians
did not indicate which groups of patients were more
likely to be overly optimistic.
Critical treatment success factors. Patients identi-
ﬁed three main factors contributing to the successful
management and treatment of cancer: having the
support of others, maintaining a positive attitude
and interacting with medical professionals (Fig. 1).
The majority of those who described the impor-
tance of moral support were women; however, there
was no difference by age group. Patients stressed
the importance of positive interaction with medical
professionals, citing the support and guidance they
received from the doctors, nurses, and medical staff
who cared for them. One patient described the help
she received from her doctor: “He gave me conﬁ-
dence to get through this, that it would all be worth
it.”
Perceptions of how patients cope with their dis-
eases and treatments were consistent among clini-
cians and, for the most part, corroborated patients’
opinions. Emotional support was the predominate
factor related to patient ability to cope with cancer
in a positive way. Clinicians explained that family
and friends are the primary source of this support.
Other support sources mentioned were nurses,
social workers, therapists, and support groups. One
nurse felt strongly that positive attitudes affect
patients’ outcomes. She explained, “If they don’t
have that positiveness that they will get better, if
they don’t have that faith, that something, to me,
they’re just not going to live as long as the positive
one who is in a positive state.” One physician
also cited antidepressants, alternative medicines,
and imaging as examples of ways patients cope with
their illnesses. The coping methods mentioned by
the patients, clinicians, and nurses, of which these
are just a few examples, may be essential factors in
effective disease management and ultimately,
satisfaction.
Satisfaction. Throughout the interview, patients
were asked a series of questions that attempted to
assess their satisfaction with chemotherapy treat-
ment and their faith in their medical team—both
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important factors in patient adherence. To assess
whether or not they were satisﬁed with their treat-
ment and its outcomes, patients were asked specif-
ically whether they believed chemotherapy was
worthwhile, if their hopes of chemotherapy had
been met and, if given the choice, whether they
would choose to be treated with chemotherapy
again. The vast majority of patients interviewed
stated that they found chemotherapy worthwhile,
either because of remission of cancer or the oppor-
tunity to live longer. Most patients also reported
that treatment was not as bad as they had antici-
pated. One patient said, “I was surprised that I
wasn’t as sick as I thought I would be.” The major-
ity of participants also stated that they would repeat
the chemotherapy again if given the choice.
Regarding the beneﬁts of chemotherapy, breast
cancer patients most often cited the reduction or
elimination of cancer. Colorectal cancer patients
reported increased general well-being almost as
often as they reported the reduction or elimination
of cancer, whereas lung cancer patients most often
reported prolonged life as the key beneﬁt. For early-
stage patients, prolonging life and reducing or elim-
inating cancer were equally important. Advanced-
stage patients, on the other hand, felt that pro-
longed life was the most fundamental gain. Finally,
survivors stated that reducing or eliminating the
tumor was chemotherapy’s most signiﬁcant beneﬁt.
Nurses and physicians indicated that patients per-
ceive satisfaction as directly related to whether or
not treatment was successful. Some nurses did men-
tion patients who had high hopes for a cure and
became very angry after ﬁnding out their tumors
had progressed despite treatment.
Patient satisfaction with treatment is a function
that is intrinsically tied to patients’ treatment expec-
tations. Thus, it is not surprising that patients’
descriptions of satisfaction reﬂect their expecta-
tions. Breast cancer, early-stage and survivor pa-
tients detailed expectations for tumor reduction and
a cure. They also described reduction or elimination
of cancer as a treatment beneﬁt. Therefore, these
patients were most satisﬁed with treatment when
they experienced tumor shrinkage or remission.
Conversely, colorectal, lung, and advanced-stage
patients, who most often expected prolonged life or
decreased disease severity, were most satisﬁed when
treatment improved the quality of their life or
helped them live longer.
IV chemotherapy versus oral chemotherapy and
Adherence. Patients’ negative reactions toward
receiving chemotherapy intravenously can be
grouped into two main categories. One group of
reactions focused on the inconvenience of IV treat-
ments, particularly in terms of the amount of time
needed for treatment and the burden of arranging
transportation. The other set of negative reactions
concerned the physical and mental effects of receiv-
ing medication through a needle and in a medical
environment. Although some patients described the
Figure 1 Success factors by cancer type.
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positive experience of interacting with other
patients when receiving treatment, patients’ com-
ments indicate that visiting the hospital or clinic is
at times depressing. For example, one patient
described the emotional impact of visiting the clinic:
“I have to watch everybody else receive  treat-
ment . . . It’s sad. It’s very sad, and that can bring
down your mental attitude.”
The United States, UK, and French patients cited
concern about needles and associated pain as their
primary fear related to IV therapy. This concern was
noted by more than half of the breast, colorectal,
and lung cancer patients. Constraints on time, con-
cerns about transportation, depression associated
with the treatment experience and the constant
reminder of serious illness were secondary concerns
expressed across the three groups. Concern about
pain and needles was the primary source of anxiety
across all three cancer stages. Early-stage cancer
patients were most likely to express this concern,
with 56% (n = 18/32) citing it as a central issue.
Additionally, early-stage patients described depres-
sion as a primary concern (13%, n = 4/32), but
were also most likely to note positive aspects of IV
therapy, such as regular contact with medical staff
and social support. These differences most likely
emerge because early-stage patients are relatively
healthy and generally have not adjusted to seeing
people ill and close to death, have greater levels of
fear due their lack of experience with chemotherapy
and may therefore seek out support from both med-
ical staff and other patients more enthusiastically.
Moreover, patients cited many positive aspects of
oral chemotherapy treatment, including conven-
ience, timesavings, and the painless method of
administration. These positive attributes of oral
chemotherapy directly counter the negative aspects
of IV therapy (inconvenience and mental and phys-
ical pain) cited in the previous section. Additionally,
patients stated that taking an oral chemotherapy
medication at home versus IV medication in a med-
ical setting, helped them to feel more “normal” and
in control of their lives. For instance, one patient
stated, “If I could just have the pills it would still
give more freedom in my life . . . I guess I would feel
that my whole life wasn’t necessarily involved
around my cancer treatment.”
Subjects expressed mixed opinions about
whether it would be easier to comply with an IV or
an oral chemotherapy treatment regimen. The
majority of patients who believed it would be easier
to take oral chemotherapy were individuals in the
65 to 75 years age group. Patients who thought that
an oral chemotherapy regimen would be more dif-
ﬁcult to follow generally fell into the 38 to 54 years
age group. Nonetheless, many participants were
unsure and felt unable to judge whether or not
adherence with an oral chemotherapy regimen
would be easier.
Breast and lung cancer patients were more likely
than colorectal cancer patients to perceive conven-
ience as an advantage of oral chemotherapy. Time
appeared to be a more important issue for colorec-
tal cancer patients, whereas breast cancer patients
noted general concerns about side effects more fre-
quently. Convenience was the primary advantage of
oral chemotherapy reported by both advanced-
stage and survivor patients. In contrast, the issue
of convenience was less important to early-stage
patients, who viewed time and independence as
the two most signiﬁcant advantages of oral chemo-
therapy. Both early-stage and survivor patients
were concerned about the side effects of oral
chemotherapy.
Clinicians’ perceptions regarding differences
between IV treatment and oral chemotherapy were
similar. They generally stated that different side
effects present in patients receiving IV versus oral
chemotherapy. Clinicians explained that patients
receiving oral chemotherapy have more gastrointes-
tinal side effects, thus raising concerns about
whether the drug gets absorbed completely before
any vomiting that may occur. However, one nurse
commented that IV medications were “stronger”
and therefore caused more side effects. Another
nurse mentioned that neutropenia (a blood disorder
that may be caused by chemotherapy) was a more
common problem with IV medications.
Regarding treatment efﬁcacy, clinicians generally
did not perceive signiﬁcant differences between IV
and oral chemotherapy treatments. However, one
physician did discuss the potential for oral chemo-
therapy medication to be less effective, adding that
this is “related to noncompliance.” Conversely,
another physician used the example of Xeloda (an
oral chemotherapy agent), and explained that this
treatment has equal efﬁcacy to IV drugs. In his opin-
ion, IV is “not the only way to administer drugs,
except that it bypasses the intestinal tract, where
they may not be absorbed properly or may be
destroyed.”
Physicians stated that the primary advantage of
oral chemotherapy medication is that patients can
take the medication at home. This enables patients
to spend less time at the clinic, away from their
daily life activities. However, physicians also
explained that they would be concerned about
whether patients were taking the medication prop-
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erly or not, and whether the drug has consistent
absorption rates when taken orally. When provided
with a hypothetical scenario in which a particular
medication has the same efﬁcacy and bioavailability
in both oral and IV forms, physicians indicated that
patient preference is the deciding factor for whether
patients would receive oral or IV chemotherapy.
The majority of physicians perceived patient prefer-
ence to be for oral chemotherapy.
Overall, patients cited efﬁcacy as their foremost
treatment priority. In addition, the majority of
patients, regardless of cancer type, stage or nation-
ality, cited concern about needles and associated
pain as the primary disadvantage of IV chemother-
apy. Moreover, their primary treatment concern
after efﬁcacy was convenience. Patients felt that
convenience was the primary advantage of oral
chemotherapy over IV, particularly for the ways
convenient treatment decreases disruption of daily
life activities, increases feelings of normality and
independence, provides more time to spend with
family and friends and reduces limitations. Early-
stage patients were more speciﬁc than advanced-
stage or survivor patients when discussing oral
chemotherapy’s improved convenience. These
patients indicated that time and independence are
the primary advantages of oral chemotherapy.
Item Generation Summary
The item generation interviews were conducted to
identify the issues patients consider when evaluating
the overall risks and beneﬁts of chemotherapy in
terms of life extension, tumor reduction/eradication
and side effects. The perceptions and comments
participants offered in these interviews and their
verbatim word choices were the primary sources for
developing questions. The analysis of patient, phy-
sician, and nurse interviews resulted in the genera-
tion of a draft of the Cancer Therapy Satisfaction
Questionnaire (CTSQ) that contained 33 items
and assessed the following domains: Conﬁdence in
treatment, Activities of daily living/side effects or
pain, Adherence, Satisfaction with treatment, and
Treatment preference/Trade-off. Skip patterns were
included for those items that were not applicable to
patients taking only IV cancer therapy versus those
taking only oral therapy. This questionnaire was
designed to be used in a range of oncology trials to
assess patients’ satisfaction with chemotherapy
treatments. The next step in the instrument devel-
opment process was to test the CTSQ in a group of
patients to assess the content validity of the items.
Content Validity Testing
Thirty respondents, 14 male and 16 female, com-
pleted the CTSQ. Ten respondents with breast
cancer, 10 respondents with lung cancer and 10
respondents with colorectal cancer participated.
Advanced-stage respondents represented 43%
(n = 13) of the population and early-stage and
survivor respondents represented 30% (n = 9) and
27% (n = 8), respectively. The majority of
advanced-stage respondents had colorectal cancer.
Three percent of the total population (n = 1) was
taking oral chemotherapy and 20% (n = 6) was tak-
ing a combined IV and oral regimen. The mean
age of the study population was 58 years (±11). The
mean age of colorectal cancer respondents was
higher than that of lung and breast cancer respond-
ents by three and six years, respectively. Table 3
Table 3 Content validity—demographics by cancer type
Breast Lung Colorectal Total
Sex, n (%)
Male 0 (0%) 9 (90%) 5 (50%) 14 (47%)
Female 10 (100%) 1 (10%) 5 (50%) 16 (53%)
Age 55 ± 14 (37–74) 58.7 ± 11.5 (41–75) 61.6 ± 7 (51–72) 58.5 ± 11
Stage, n (%)
Early 1 (10%) 4 (40%) 4 (40%) 9 (30%)
Advanced 2 (20%) 5 (50%) 6 (60%) 13 (43%)
Survivor 7 (70%) 1 (10%) 0 (0%) 8 (27%)
Receiving chemotherapy
currently, n (%)
Yes 2 (20%) 9 (90%) 9 (90%) 20 (67%)
No 8 (80%) 1 (10%) 1 (10%) 10 (33%)
Form of chemotherapy, n (%)
IV 8 (80%) 8 (80%) 7 (70%) 23 (77%)
IV and oral 1 (10%) 2 (20%) 3 (30%) 6 (20%)
Oral 1 (10%) — — 1 (3%)
Number of cycles of 
chemotherapy in the last
year (for nonsurvivors)
5.5 ± 2 8 ± 6 7.2 ± 5 6.9 ± 1.3
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provides the demographic information of respond-
ents included in the content validity interviews.
The mean amount of time it took to complete the
questionnaire was 13 min (±6.5), which ranged
from 6.5 to 19.5 min. Overall, respondents felt the
questionnaire was clear, comprehensive, relevant,
and easy to complete. Some revisions were suggested
to improve clarity, resulting in deletion of 12 items
and modiﬁcation of 17 items. Deleted items tended
to be those that speciﬁed patient preferences for one
type of product over another. These items were not
relevant to those who had only taken one type of
product. Modiﬁcations were minor and pertained to
removing the word “conﬁdent” from the expecta-
tion questions, and using the word “take” instead of
“have” in relation to chemotherapy, This version of
the CTSQ is comprised of 21 items and ﬁve multi-
item domains: Expectations of chemotherapy,
Feelings about side effects, Oral chemotherapy
adherence, Convenience related to treatment, and
Satisfaction with chemotherapy. Two single items
assess two additional concepts related to adherence:
Frequency of thinking about stopping chemother-
apy and Reasons for nonadherence.
Retesting of the Questionnaire
Results from the retest of the revised questionnaires
suggested that although the content and the objec-
tives of the questionnaire were clearly understood
and endorsed by patients on oral therapy, patients
had difﬁculty relating to a questionnaire that used
the word “chemotherapy (IV/pills)” throughout,
thinking that this included only chemotherapy
treatment and not hormonal therapy. Consequently,
patients tended to recall back to the time they were
receiving chemotherapy, which may induce recollec-
tion bias and was not the focus of the administra-
tion. Based on this set of cognitive debrieﬁng
interviews, the CCSQ was modiﬁed to address
patients’ oral and IV therapy by replacing “chemo-
therapy” with “cancer therapy (IV/pills),” making it
applicable to a those on hormonal therapy. This
wording was also tested in the cognitive debrieﬁng
and found to be acceptable to patients. This prevali-
dated version of the questionnaire can be found in
the appendix.
Discussion
The CTSQ has been developed following a rigorous
methodology and is currently undergoing psycho-
metric validation to assess its reliability and validity
in a number of tumor types. This validation study
may also be used to further reﬁne the questionnaire
and to develop ﬁnal scoring methods, thus the items
and hypothesized domains provided herein may
change pending the results of the validation study.
In developing the CTSQ, care was taken to
design questions that are relevant to many cancer
patients to produce a questionnaire that would be
applicable regardless of cancer stage and type,
country of residence or cancer therapy. Differences
by country were minor. However, several differ-
ences in responses by patient type and stage in a
number of areas were noted, although the main
concepts were similar across patients. However, all
breast cancer patients and the majority of early-
stage patients were female, thus it is unclear if
observed differences by treatment type and stage
were due to type or stage of cancer, or to sex dif-
ferences. If implemented in larger scale studies, the
CTSQ may help to further understand the experi-
ences of patients in different stages or types of can-
cer or treatment.
The CTSQ encompasses several key components
of satisfaction: expectations and the meeting of
those expectations which may ultimately result in
satisfaction and potentially enhanced treatment
adherence. The CTSQ focuses on patients’ satisfac-
tion with efﬁcacy, tolerability, and convenience.
Adherence has also been included, because this may
be an important issue in oral therapy regimens.
In line with the above theory, patients in our
study who had higher expectations of chemother-
apy also expressed greater satisfaction with therapy.
For example, breast cancer patients, survivors, and
early-stage patients expressed high treatment expec-
tations, often including a cure. Consequently, these
patients discussed treatment satisfaction and treat-
ment beneﬁts in terms of the treatment’s ability to
reduce or eliminate cancer. Advanced-stage, color-
ectal, and lung cancer patients were less optimistic
or perhaps, realistic given their situation, and,
accordingly, were more likely to detail expectations
of prolonged life or decreased cancer severity.
Patients across all types and stages of cancer dis-
cussed efﬁcacy as their main treatment priority,
cited concern about needles and associated pain as
the primary disadvantage of IV chemotherapy and
stated that convenience was the central advantage
of oral over IV chemotherapy. When discussing oral
chemotherapy’s improved convenience, early-stage
patients were more speciﬁc than advanced-stage or
survivor patients, describing time and independence
as primary advantages. Patients, clinicians, and
nurses also identiﬁed other critical treatment suc-
cess factors, such as social support, positive atti-
tude, and positive patient/doctor interactions and
Abetz et al.S50
communication, which may play important moder-
ating roles in the assessment of treatment satisfac-
tion; further research in this area is warranted
utilizing appropriate questionnaires to assess these
constructs.
Although the CTSQ was developed for use
throughout stages of cancer, the study was con-
ducted with ambulatory patients and additional
research is warranted if it is to be used in nonam-
bulatory advanced-stage patients. Further quantita-
tive research utilizing the CTSQ would help to
answer these questions.
Conclusion
The CTSQ was developed multiculturally and was
based on extensive interviews with 70 oncology
patients with a variety of cancer types/stages, seven
clinicians (from community and academic settings),
four nurses and focus groups with 14 nurses (from
hospital and community settings) and following by
content validity testing in 30 patients and retesting
in an additional 10 patients. The CTSQ assesses
pertinent domains identiﬁed from the satisfaction
literature and domains that match issues most rele-
vant to patients. The CTSQ’s practical aim makes
it a very good communication tool because it
addresses the concerns of clinicians and patients. In
addition, the CTSQ may address some needs of
health authorities that are increasingly requesting
information regarding the trade-offs that patients
make when assessing whether or not to continue
treatment. It is hoped that with psychometric vali-
dation the CTSQ will be appropriate for use in a
range of oncology areas to assess patient satisfac-
tion with cancer therapy.
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Appendix: Cancer Therapy Satisfaction Questionnaire (Prevalidated Version)
• The following pages ask some questions about your cancer therapy (IV/pills). Within this questionnaire,
“Cancer therapy (IV/pills)” refers to your current or most recent cancer therapy or cancer pills (includ-
ing: hormonal therapy, IV therapy, and cancer pills).
• Please read each question and answer as honestly as you can without the help of anyone.
• There are no right or wrong answers; the answers should be based on your own personal experiences.
• All of your answers will remain conﬁdential.
• This questionnaire will take about 10 min to complete.
Your Thoughts about Cancer Therapy (IV/pills)
The following statements ask you to share your thoughts about cancer therapy (IV/pills). Please answer each
question below by checking the box that best represents your opinion (check only one box per question).
9. In general, in the last four weeks, how often did you think about stopping your cancer therapy (IV/pills)?
In general, in the last four weeks, how often 
did you feel: Always Most of the time Sometimes Rarely Never
1. That cancer therapy (IV/pills) would help
you to return back to a normal life?
5 4 3 2 1
2. That cancer therapy (IV/pills) would get
rid of the cancer?
5 4 3 2 1
3. That cancer therapy (IV/pills) would help
prevent the cancer from coming back?
5 4 3 2 1
4. That cancer therapy (IV/pills) would stop
the cancer from spreading?
5 4 3 2 1
5. That your cancer therapy (IV/pills)
limited your daily activities?
5 4 3 2 1
6. Upset about the side effects? 5 4 3 2 1
7. That cancer therapy (IV/pills) was worth
taking even with the side effects?
5 4 3 2 1
8. That cancer therapy (IV/pills) would
help you live longer?
5 4 3 2 1
5 4 3 2 1
Always Most of the time Sometimes Rarely Never
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If you are receiving only IV cancer therapy, skip 10, 11, and 12 and continue with question 13. If you are
receiving cancer pills, please answer the questions below.
If you answered “always” to question 11, please skip question 12 and continue with question 13.
12. If you did not always take cancer pills as directed, why didn’t you?
(Please check all that apply)
1 I forgot
2 It was inconvenient
3 I felt I needed a break
4 I felt I did not need it
5 Side effects.
Satisfaction with Cancer Therapy (IV/pills)
The following statements are about your satisfaction with your most recent cancer therapy (IV/pills). Please
answer each question below by checking the box that best describes your level of satisfaction (check only one
box per question).
13. Overall, how inconvenient was it for you to take your cancer therapy (IV/pills)?
14. Overall, how bothered were you by the amount of time it took to take your cancer therapy (IV/pills)?
15. Overall, how worthwhile was your cancer therapy (IV/pills)?
16. Overall, was taking cancer therapy (IV/pills) as difﬁcult as you expected?
17. Overall, how well did the beneﬁts of cancer therapy (IV/pills) meet your expectations?
18. Overall, were the side effects of cancer therapy (IV/pills) as you expected?
In general, in the last four weeks, how
often did you: Always Most of the time Sometimes Rarely Never
10. Have trouble remembering to take
your cancer therapy pills?
5 4 3 2 1
11. Take your cancer therapy exactly
as directed by your doctor?
5 4 3 2 1
5 4 3 2 1
Very convenient Convenient Neither convenient
nor inconvenient
Inconvenient Very Inconvenient
5 4 3 2 1
Very bothered Quite bothered Moderately bothered A little bothered Not bothered at all
5 4 3 2 1
Very
worthwhile
Quite
worthwhile
Moderately
worthwhile
A little
worthwhile
Not worthwhile
at all
5 4 3 2 1
Much more difﬁcult
than I thought it
would be
Somewhat more
difﬁcult than I
thought it would be
As difﬁcult as I
thought it would be
Somewhat easier
than I thought it
would be
Much easier 
than I thought it
would be
5 4 3 2 1
Much better than
my expectations
Somewhat better
than my
expectations
Met my
expectations
Somewhat worse
than my
expectations
Much worse
than my
expectations
5 4 3 2 1
Much better than
I expected
Somewhat better
than I expected
Exactly as
I expected
Somewhat worse
than I expected
Much worse than
I expected
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19. How satisﬁed were you with the form of your cancer therapy (IV/pills)?
20. Overall, how satisﬁed were you with your most recent cancer therapy (IV/pills)?
21. Taking everything into consideration, if given the choice again, would you decide to take this cancer
therapy treatment?
Thank you for your help.
5 4 3 2 1
Very satisﬁed Satisﬁed Neither satisﬁed nor dissatisﬁed Dissatisﬁed Very dissatisﬁed
5 4 3 2 1
Very satisﬁed Satisﬁed Neither satisﬁed nor dissatisﬁed Dissatisﬁed Very dissatisﬁed
5 4 3 2 1
Yes, deﬁnitely Probably Yes I don’t know Probably not Deﬁnitely not
